Tillotts in the UK

Tillotts Pharma UK is proud to be based in Lincolnshire and is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, part of the Japanese Zeria Group.


Tillotts Pharma UK Ltd was established in March 2010. Jeremy Thorpe (Managing Director) joined in July 2012, with a clear focus on optimising the portfolio of gastrointestinal (GI) health products.

Today, Tillotts Pharma UK employs over 45 people from across the UK.

GI health is our passion at Tillotts

With over 30 years’ expertise in developing and manufacturing treatments for inflammatory bowel disease (IBD), we understand the disease, the market and the challenges GI healthcare professionals and patients face.

Tillotts Pharma UK is a market leader in GI health products and provides support in the following areas:

  • Inflammatory Bowel Disease
  • Clostridioides difficile Infections

Enhancing patient care

Tillotts Pharma UK strive to be the preferred partner in GI health and are committed to supporting the NHS to improve outcomes for patients. Tillotts are motivated by the aim to consistently deliver quality and value to the NHS and are dedicated to improving the lives of people with GI disease and supporting those who care for them.

Supporting healthcare professionals

We organise dedicated educational initiative, Tillotts LOGIC, to support healthcare professionals enhance patient care.


An award-winning organisation

Tillotts Pharma UK have recently received several industry recognised awards, including Gold and Silver PM Society Awards in 2018 and a Gold Communiqué Award in 2019 for Excellence in Communication via Meetings. Tillotts Pharma UK has also been recognised internally, winning an internal Star Award for being the best performing affiliate, for maintaining seven consecutive years of double digit growth.

Seeking partnerships

Tillotts actively seeks partnership and in-licensing opportunities, to add to our portfolio of medicines for disease of the digestive system. We are particularly interested in products which may be off patent or are currently not being actively promoted where we can breathe life back into the brand, help fulfil any unmet patient needs and provide value to the NHS.

NU-01427 November 2021